Aishwarya Ravindran
Overview
Explore the profile of Aishwarya Ravindran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ravindran A, Goyal G, Morlote D, Mackinnon A
Blood Res
. 2025 Feb;
60(1):13.
PMID: 40019725
No abstract available.
2.
Evers 3rd C, Ravindran A, Rosenblum F, Weber F
ACG Case Rep J
. 2025 Feb;
12(3):e01627.
PMID: 40018696
Castleman disease (CD) is a rare group of lymphoproliferative disorders subdivided based on clinical features. Although not fully understood, the pathogenesis of both CD and Crohn's disease involves a combination...
3.
Acosta-Medina A, Abeykoon J, Zanwar S, Ruan G, Rech K, Ravindran A, et al.
Leukemia
. 2025 Feb;
PMID: 39934281
No abstract available.
4.
Makras P, Erickson D, Davidge-Pitts C, Diamond E, Allen C, McClain K, et al.
J Clin Endocrinol Metab
. 2024 Dec;
PMID: 39699236
Endocrinopathies are frequently the initial presentation of histiocytic neoplasms, which are rare hematologic disorders affecting multiple organ systems. Langerhans cell histiocytosis and Erdheim-Chester disease are 2 such disorders known to...
5.
Smith K, Acosta-Medina A, Dasari S, Ranatunga W, Rech K, Ravindran A, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400471.
PMID: 39576953
Purpose: BRAF and MEK inhibitors are standard treatments in histiocytic disorders, such as Erdheim-Chester disease (ECD). Some patients lack MAPK-pathway alterations, making these treatments less effective. Methods: We describe three...
6.
Banks S, Decker P, Flanagan E, Zekeridou A, Go R, Abeykoon J, et al.
Blood Cancer J
. 2024 Sep;
14(1):153.
PMID: 39237493
No abstract available.
7.
Nathoo N, Uhm J, Porter A, Hammack J, Jaeckle K, Mrugala M, et al.
Blood Cancer J
. 2024 Jun;
14(1):101.
PMID: 38902249
No abstract available.
8.
Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis
Ruan G, Zanwar S, Ravindran A, Schram S, Abeykoon J, Hazim A, et al.
Am J Hematol
. 2024 Feb;
99(5):871-879.
PMID: 38409747
Malignant histiocytosis (MH) is an extremely rare neoplasm of the macrophage-dendritic cell lineage. We report the clinical characteristics, molecular aberrations, treatments, and outcomes of patients with MH seen at two...
9.
Ravindran A, Macon W, Rech K
J Hematop
. 2024 Feb;
15(1):45-46.
PMID: 38358600
No abstract available.
10.
Goyal G, Acosta-Medina A, Abeykoon J, Dai C, Ravindran A, Vassallo R, et al.
Blood Adv
. 2023 Sep;
7(21):6568-6578.
PMID: 37698994
Advances in the treatment of Langerhans cell histiocytosis (LCH) have resulted in a growing survivor population. There is a lack of data on long-term outcomes among adults with LCH. We...